SMMT
Summit Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SMMT fundamentals
Summit Therapeutics (SMMT) released its earnings on Oct 20, 2025: revenue was 0 (YoY 0.00%), missed estimates; EPS was -0.13 (YoY -160.00%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.13
-160.00%
Report date
Oct 20, 2025
SMMT Earnings Call Summary for Q3,2025
- Breakthrough NSCLC Data: ivonescimab + chemo delivered 4.24-month PFS improvement (HR 0.60) in HARMONi-6, outperforming tislelizumab across PD-L1 subgroups.
- Global Expansion: 14 Phase III studies underway, including first colorectal cancer trial with 600-patient enrollment.
- FDA Filing Momentum: BLA submission for EGFR-mutant NSCLC planned Q4 2025; $238.6M cash runway supports aggressive development.
- Safety Validation: ivonescimab tolerable in high-risk squamous NSCLC patients with central tumors and hemoptysis history.
EPS
Revenue
Revenue & Expenses
Key Indicators
Summit Therapeutics (SMMT) key financial stats and ratios, covering profitability, financial health, and leverage.
Summit Therapeutics (SMMT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Summit Therapeutics (SMMT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Summit Therapeutics (SMMT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Summit Therapeutics (SMMT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Summit Therapeutics (SMMT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Summit Therapeutics’s earnings call?What is the market's earnings forecast for Summit Therapeutics next quarter?What guidance did Summit Therapeutics's management provide for the next earnings period?Did Summit Therapeutics beat or miss consensus estimates last quarter?What is Summit Therapeutics's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Summit Therapeutics year over year?What does Summit Therapeutics do and what are its main business segments?What is Summit Therapeutics's gross profit margin?
